Iterum Therapeutics plc announced the U.S. launch of Orlynvah (sulopenem etzadroxil and probenecid) oral tablets. The FDA had approved Orlynvah for adult women with uncomplicated urinary tract infections… read more.
Gilead Sciences Inc. announced that the European Commission (EC) has granted marketing authorization for Yeytuo (lenacapavir)—the company’s twice-yearly injectable HIV-1 capsid inhibitor—for use as pre-exposure prophylaxis (PrEP) to… read more.
Madrigal Pharmaceuticals Inc. announced that the European Commission (EC) has granted conditional marketing authorization for Rezdiffra (resmetirom) for the treatment of adults with noncirrhotic MASH with moderate to… read more.
Biogen Inc and Stoke Therapeutics Inc, a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, announced presentations of new clinical data… read more.
Ionis Pharmaceuticals,Inc. announced that the FDA has approved Dawnzera (donidalorsen) for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age… read more.
BeOne Medicines Ltd. announced that the European Commission has approved a new film-coated tablet formulation of Brunkinsa (zanubrutinib) for all approved indications. “Developed to meet the real-world needs… read more.
In its latest (Q2) earnings report, Iovance confirmed plans to reduce its workforce by 19% in a bid to save $100 million in yearly costs due to lower… read more.
Idorsia announced that The Galien Foundation, a premier global institution dedicated to honoring innovators in life sciences, has nominated Tryvio (aprocitentan) in the category of “Best Pharmaceutical Product”… read more.
Precigen, Inc. announced that the FDA has approved Papzimeos (zopapogene imadenovec-drba) for the treatment of adults with recurrent respiratory papillomatosis (RRP). Papzimeosis the first and only FDA-approved therapy… read more.
Iovance Biotherapeutics Inc. announced Health Canada has issued a Notice of Compliance with Conditions (NOC/c) for Amtagvi (lifileucel), a tumor-derived autologous T cell immunotherapy. Amtagvi is indicated for… read more.
The FDA has updated Skysona’s indication, allowing it to be used only in patients who do not have an available human leukocyte antigen (HLA)-matched donor for stem cell… read more.
Novo Nordisk announced that the FDA has approved an additional indication for Wegovy (semaglutide 2.4 mg) based on a supplemental New Drug Application (sNDA) for treatment of noncirrhotic… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
